Showing results (71-80 of 84) with videos related to
Sort By:
Pageof 9
Clinical and Experimental Dermatology|November 9, 2025
Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitisJonathan I Silverberg, Andreas Wollenberg, Linda Stein Gold, et al.The Journal of Allergy and Clinical Immunology. in Practice|February 15, 2024
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 PopulationJonathan Corren, Stanley J Szefler, Ellen Sher, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|July 11, 2024
Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitisJonathan I Silverberg, Melinda Gooderham, Norito Katoh, et al.Dermatology and Therapy|February 12, 2026
Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 StudiesAndrew Blauvelt, Leon Kircik, Eric L Simpson, et al.The Journal of Allergy and Clinical Immunology|February 5, 2013
Atopic dermatitis: a practice parameter update 2012Lynda Schneider, Stephen Tilles, Peter Lio, et al.The Journal of Allergy and Clinical Immunology. in Practice|August 21, 2022
Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-AnalysisPaul Oykhman, Jared Dookie, Husam Al-Rammahy, et al.The Journal of Allergy and Clinical Immunology. in Practice|January 16, 2021
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic DermatitisMark Boguniewicz, Lisa A Beck, Lawrence Sher, et al.JAMA Dermatology|October 23, 2024
Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 WeeksAmy S Paller, Pedro Mendes-Bastos, Elaine Siegfried, et al.JAMA Dermatology|April 12, 2023
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical TrialsAmy S Paller, Barry Ladizinski, Pedro Mendes-Bastos, et al.Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 3, 2022
Bleach baths for atopic dermatitis: A systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADELayla Bakaa, Jeffrey M Pernica, Rachel J Couban, et al.Pageof 9